The 14-3-3 Protein ε Isoform Expressed in Reactive Astrocytes in Demyelinating Lesions of Multiple Sclerosis Binds to Vimentin and Glial Fibrillary Acidic Protein in Cultured Human Astrocytes

Jun-ichi Satoh,* Takashi Yamamura,* and Kunimasa Arima†

From the Department of Immunology,* National Institute of Neuroscience, and the Department of Neuropathology,† National Center Hospital for Mental, Nervous, and Muscular Disorders, National Center of Neurology and Psychiatry, Tokyo, Japan

The 14-3-3 protein family consists of acidic 30-kd proteins expressed at high levels in neurons of the central nervous system. Seven isoforms form a dimeric complex that acts as a molecular chaperone that interacts with key signaling components. Recent studies indicated that the 14-3-3 protein identified in the cerebrospinal fluid of various neurological diseases including multiple sclerosis (MS) is a marker for extensive brain destruction. However, it remains unknown whether the 14-3-3 protein plays an active role in the pathological process of MS. To investigate the differential expression of seven 14-3-3 isoforms in MS lesions, brain tissues of four progressive cases were immunolabeled with a panel of isoform-specific antibodies. Reactive astrocytes in chronic demyelinating lesions intensely expressed ε, ε, ζ, η, and σ isoforms, among which the ε isoform is a highly specific marker for reactive astrocytes. Furthermore, protein overlay, mass spectrometry, immunoprecipitation, and double-immunolabeling analysis showed that the 14-3-3 protein interacts with both vimentin and glial fibrillary acidic protein in cultured human astrocytes. These results suggest that the 14-3-3 protein plays an organizing role in the intermediate filament network in reactive astrocytes at the site of demyelinating lesions in MS. (Am J Pathol 2004, 165:577–592)

The 14-3-3 protein family consists of evolutionarily conserved, acidic 30-kd proteins originally identified by two dimensional analysis of brain protein extract.1–4 Seven isoforms of the 14-3-3 protein named β, γ, ε, ζ, η, θ (also termed as τ), and σ have been identified in eukaryotic cells. Although the 14-3-3 protein is widely distributed in neural and nonneural tissues, it is expressed most abundantly in neurons in the central nervous system (CNS), where it represents 1% of total cytosolic proteins.4–7 A homodimeric or heterodimeric complex, which is composed of the same or distinct isoforms of the 14-3-3 protein, constitutes a large cup-like structure with two ligand-binding sites in its groove. The dimeric complex acts as a novel molecular chaperone that interacts with key molecules involved in cell differentiation, proliferation, transformation, and apoptosis.1–4 It regulates the function of target proteins by restricting their subcellular location, bridging them to modulate catalytic activity, and protecting them from dephosphorylation or proteolysis.1–4,8–10 In general, the 14-3-3 protein binds to phosphoserine-containing motifs of the ligands such as RXXpSXP and RXY/FXpSXP in a sequence-specific manner.1–3,10 More than 100 proteins have been identified as being 14-3-3 binding partners, including a range of intracellular signaling regulators such as Raf, BAD, protein kinase C (PKC), phophatidylinositol 3-kinase (PI3K), and cdc25 phosphatase.1–4,8–10 Binding of the 14-3-3 protein to Raf is indispensable for Raf kinase activity in the Ras/MAPK signaling pathway, whereas 14-3-3 binding to the mitochondrial Bcl-2 family member BAD, when phosphorylated by a serine/threonine kinase Akt, inhibits apoptosis.1–4 In addition to the phosphorylation-dependent interaction, the 14-3-3 protein can interact with a set of target proteins in a phosphorylation-independent manner.10–12 The ε isoform binds to p180RhoGEF via a phosphoserine-independent interaction.11

Previous studies indicated that the 14-3-3 protein has isoform-specific and nonredundant functions.1–4 Synaptic transmission and associative learning are impaired in...


Drosophila mutants lacking the \( \zeta \) protein.\textsuperscript{13} The 14-3-3 isoforms have distinct affinities for their target proteins. A preferential interaction is observed between PKC\( \varepsilon \) and the human 14-3-3 isoform in T cells.\textsuperscript{14} IGF1-receptor, IRS1, and \( \epsilon \) isoform,\textsuperscript{15} the apoptosis-inhibitor A20 and the human \( \beta \) and \( \eta \) isoforms,\textsuperscript{16} and glucocorticoid receptor and the human \( \gamma \) isoform.\textsuperscript{17} The human \( \beta \) and \( \zeta \) isoforms and not \( \gamma \) or \( \epsilon \) isoforms interact with phosphorylated tau.\textsuperscript{18} Furthermore, different isoforms show distinct patterns of spatial, temporal, and subcellular distribution. The human \( \theta \) and \( \sigma \) isoforms are predominantly expressed in T cells and epithelial cells, respectively.\textsuperscript{14,19}

In the developing rat brain, defined populations of neurons express \( \beta \), \( \gamma \), \( \zeta \), and \( \theta \) isoforms at specific stages of development.\textsuperscript{5,7} In the adult mouse brain, \( \beta \), \( \gamma \), \( \eta \), and \( \zeta \) isoforms are widely distributed with the localization primarily in neurons, although some glial cells express \( \epsilon \), \( \theta \), and \( \zeta \) isoforms.\textsuperscript{21}

Recently, several lines of evidence have indicated that the 14-3-3 protein is involved in neurodegenerative processes. The 14-3-3 protein detected in the cerebrospinal fluid of Creutzfeldt-Jacob disease has been used as a biochemical marker for the premortem diagnosis of Creutzfeldt-Jacob disease in the context of differential diagnosis of progressive dementia.\textsuperscript{22–24} In addition, intense immunoreactivity against the \( \zeta \) isoform was identified in amyloid plaques in the Creutzfeldt-Jacob disease brain.\textsuperscript{25} However, several studies including our own showed that the 14-3-3 protein is occasionally detectable in the cerebrospinal fluid of infectious meningoencephalitis, metabolic encephalopathy, cerebrovascular diseases, and multiple sclerosis (MS) presenting with severe myelitis, suggesting that it is not a marker specific for prion diseases but for extensive destruction of brain tissues causing the leakage of 14-3-3 protein into the cerebrospinal fluid.\textsuperscript{4,22–26,27} In the Alzheimer’s disease brain, neurofibrillary tangles express immunoreactivity against the 14-3-3 protein.\textsuperscript{28} The 14-3-3\( \zeta \) homodimer interacts with tau and glycogen synthase kinase-3\( \beta \) (GSK3\( \beta \)), and stimulates GSK3\( \beta \)-mediated tau phosphorylation.\textsuperscript{29} In the Parkinson’s disease brain, Lewy bodies possess \( \gamma \), \( \epsilon \), \( \zeta \), and \( \theta \) isoforms that interact with \( \alpha \)-synuclein,\textsuperscript{30,31} Dopamine-dependent neurotoxicity is mediated by a soluble complex composed of the 14-3-3 protein and \( \alpha \)-synuclein, whose levels are markedly elevated in the substantia nigra of the Parkinson’s disease brain.\textsuperscript{32} The neurotoxicity of ataxin-1, the causative protein of spinocerebellar ataxia type 1, is enhanced by \( \epsilon \) and \( \zeta \) isoforms that bind to and stabilize ataxin-1 phosphorylated by Akt, thereby slowing its degradation.\textsuperscript{33} Finally, expression of the \( \theta \) isoform is enhanced in the spinal cord of amyotrophic lateral sclerosis.\textsuperscript{34} However, it remains unknown whether the 14-3-3 protein plays an active role in the pathological process of MS.

In the present study, we investigated the differential expression of seven 14-3-3 isoforms in chronic active demyelinating lesions of MS. We found that reactive astrocytes intensely express \( \beta \), \( \epsilon \), \( \zeta \), \( \eta \), and \( \sigma \) isoforms, among which the \( \epsilon \) isoform provides a specific marker to identify reactive astrocytes in the MS brain. Furthermore, the 14-3-3 protein interacts with vimentin and glial fibrillary acidic protein (GFAP) in cultured human astrocytes. These observations suggest that the 14-3-3 protein plays an organizing role in the intermediate filament (IF) network in reactive astrocytes at the site of demyelinating lesions in MS.

**Materials and Methods**

**MS and Non-MS Brain Tissues**

Ten-\( \mu \)-thick tissue sections were prepared from the brain, spinal cord, and optic nerve derived from four autopsy cases of MS numbered 791, 744, 609, and 544. The clinical and neuroradiological profiles of these patients are shown in a supplementary table on The American

---

**Table 1.** The 14-3-3 Isoform-Specific or Broadly Reactive Antibodies Utilized for Immunohistochemistry and Western Blot Analysis

<table>
<thead>
<tr>
<th>14-3-3 Isoforms</th>
<th>Suppliers</th>
<th>Code</th>
<th>Antigen peptide</th>
<th>Origin</th>
<th>Specificity</th>
<th>Concentration used for Immunohistochemistry (( \mu )g/ml)</th>
<th>Concentration used for Western blotting (( \mu )g/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pan</td>
<td>SC</td>
<td>sc-629</td>
<td>N-terminal</td>
<td>Rabbit</td>
<td>Reactive to all isoforms</td>
<td>0.4</td>
<td>0.04</td>
</tr>
<tr>
<td>Pan</td>
<td>SC</td>
<td>sc-1657</td>
<td>N-terminal</td>
<td>Mouse</td>
<td>Reactive to all isoforms</td>
<td>0.4</td>
<td>0.04</td>
</tr>
<tr>
<td>( \beta )</td>
<td>SC</td>
<td>sc-628</td>
<td>C-terminal</td>
<td>Rabbit</td>
<td>Reactive predominantly to ( \beta ) isoform, but crossreactive to other isoforms to a lesser extent</td>
<td>0.4</td>
<td>0.04</td>
</tr>
<tr>
<td>( \gamma )</td>
<td>IBL</td>
<td>18641</td>
<td>N-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>( \epsilon )</td>
<td>IBL</td>
<td>18647</td>
<td>C-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>5</td>
<td>0.2</td>
</tr>
<tr>
<td>( \zeta )</td>
<td>IBL</td>
<td>18643</td>
<td>C-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>( \eta )</td>
<td>IBL</td>
<td>18644</td>
<td>N-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>2</td>
<td>0.5</td>
</tr>
<tr>
<td>( \theta )</td>
<td>SC</td>
<td>sc-732</td>
<td>C-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>0.4</td>
<td>0.04</td>
</tr>
<tr>
<td>( \theta )</td>
<td>IBL</td>
<td>10017</td>
<td>Recombinant, whole Mouse</td>
<td>Minimally crossreactive to ( \epsilon ) isoform</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>( \sigma )</td>
<td>IBL</td>
<td>18642</td>
<td>C-terminal</td>
<td>Rabbit</td>
<td>Not crossreactive to other isoforms</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

**Abbreviations:** SC, Santa Cruz Biotechnology; IBL, Immunobiological Laboratory. The specificity of the antibodies (IBL) is also shown in Supplementary Figure 1 at [http://www.amjpathol.org](http://www.amjpathol.org).
sections were stained with the following antibodies: rabbit polyclonal antibody against vimentin (V9; Santa Cruz Biotechnology), mouse monoclonal antibody against GFAP (N1506; DAKO, Carpinteria, CA), rabbit polyclonal antibody against vimentin (H-84; Santa Cruz Biotechnology), mouse monoclonal antibody against vimentin (V9; Santa Cruz Biotechnology), rabbit polyclonal antibody against myelin basic protein (N1546; DAKO), mouse monoclonal antibody against CD68 (N1577; DAKO), and mouse monoclonal antibody against 70-kd and 200-kd neurofilament proteins (2F11; Nichirei). For negative controls, sections were incubated with a rabbit-negative control reagent (DAKO) instead of primary antibodies. The optimum concentrations of these antibodies and incubation periods were determined according to the supplier’s instruction.

For double-labeling immunocytochemistry, cells on cover glasses were fixed with 4% PFA in 0.1 mol/L phosphate-buffered saline at room temperature for 15 minutes with 3% H2O2-containing methanol. For vimentin immunolabeling, the tissue sections were pretreated with 0.125% trypsin solution (Nichirei, Tokyo, Japan) at 37°C for 15 minutes. They were then incubated with 10% normal goat serum containing phosphate-buffered saline (PBS) at room temperature for 15 minutes to block nonspecific staining. The sections were incubated in a moist chamber at 4°C overnight with a panel of 14-3-3 isoform-specific antibodies or with antibodies broadly reactive against all isoforms listed in Table 1. The antibodies were obtained from Immunobiological Laboratory (IBL), Gummia, Japan, and Santa Cruz Biotechnology, Santa Cruz, CA. The specificity of the antibodies from IBL is shown in Supplementary Figure 1 on The American Journal of Pathology website, and additional information on those of Santa Cruz Biotechnology is available on the supplier’s website (www.scbt.com). After washing with PBS, the tissue sections were labeled at room temperature for 30 minutes with peroxidase-conjugated secondary antibodies (Simple Stain MAX-PO kit, Nichirei) followed by incubation with a colorizing solution containing diaminobenzidine tetrahydrochloride and a counterstain with hematoxylin. To identify cell types expressing the 14-3-3 protein, adjacent sections were stained with the following antibodies: rabbit polyclonal antibody against GFAP (N1506; DAKO, Carpinteria, CA), rabbit polyclonal antibody against vimentin (H-84; Santa Cruz Biotechnology), mouse monoclonal antibody against vimentin (V9; Santa Cruz Biotechnology), rabbit polyclonal antibody against myelin basic protein (N1546; DAKO), mouse monoclonal antibody against CD68 (N1577; DAKO), and mouse monoclonal antibody against 70-kd and 200-kd neurofilament proteins (2F11; Nichirei). For negative controls, sections were incubated with a rabbit-negative control reagent (DAKO) instead of primary antibodies. The optimum concentrations of these antibodies and incubation periods were determined according to the supplier’s instruction.

Figure 1. Constitutive expression of 14-3-3 isoforms in cultured human cells.
Two μg of total protein extract isolated from brain tissues or cultured cells incubated in 10% FBS-containing medium were processed for Western blot analysis using a battery of 14-3-3 isoform-specific antibodies or the antibodies broadly reactive against all of the isoforms listed in Table 1, or the antibody against the housekeeping gene product HSP60. a to i indicate the following antibody specificity: a, all isoforms; b, HSP60; c, β, d, γ, e, f, ζ, η, θ, and i; d, HSP60; e, β, f, γ, ζ, η, θ, and i; and f, β, γ, ζ, η, θ, and i. Lanes 1 to 4 represent homogenate of the human cerebrum (lane 1), NTera2-derived differentiated neurons (NTera2-N) (lane 2), U-373MG astrocytoma cells (lane 3), fetal human astrocytes (AS1477) (lane 4), and HeLa cervical carcinoma cells (lane 5).
phate buffer (pH 7.4) at room temperature for 10 minutes, followed by incubation with PBS containing 0.5% Triton X-100 at room temperature for 20 minutes. The cells were then incubated at room temperature for 30 minutes with a mixture of 14-3-3 isofrom-specific antibody and rat monoclonal anti-GFAP antibody (2.2B10) or V9 antibody. Next, they were incubated at room temperature for 30 minutes with a mixture of rhodamine-conjugated anti-rabbit IgG and fluorescein isothiocyanate-conjugated anti-rat or mouse IgG (ICN-Cappel, Aurora, OH). After several washes, cover glasses were mounted on the slides with glycerol-polyvinyl alcohol, and the slides were examined under a Nikon ECLIPSE E800 universal microscope equipped with fluorescein and rhodamine optics. Negative controls were processed following these steps except for exposure to primary antibody.

Cell Culture

Two different sources of cultured human astrocytes were used. One was fetal human astrocytes named AS1477, provided by Drs. K. Watabe and S. U. Kim of the University of British Columbia, Vancouver, BC, Canada. They were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin (feeding medium). The other was astrocytes named ASBW, whose differentiation was induced from neuronal progenitor (NP) cells. NP cells isolated from the brain of a human fetus at 18.5 weeks of gestation were obtained from BioWhittaker (Walkersville, MD). NP cells plated on a polyethyleneimine-coated surface were incubated in DMEM/F-12 medium containing an insulin-transferrin-se-lenium supplement (Invitrogen, Carlsbad, CA), 20 ng/ml recombinant human epidermal growth factor (Higeta, Tokyo, Japan), 20 ng/ml recombinant human basic fibroblast growth factor (PeproTech EC, London, UK), and 10 ng/ml recombinant human leukemia inhibitory factor (Chemicon, Temecula, CA) (NP medium). For the induction of astrocyte differentiation, NP cells were incubated for several weeks in feeding medium instead of NP medium. This induction induced vigorous proliferation and differentiation of astrocytes accompanied by a rapid reduc-

![Figure 2. Growth-dependent expression of various 14-3-3 isoforms in cultured human astrocytes.](image)

### Table 2. Differential Expression of Seven 14-3-3 Isoforms in Glial Cells and Neurons in MS and Control Brains

<table>
<thead>
<tr>
<th>Brains</th>
<th>Astrocytes</th>
<th>Microglia/macrophages</th>
<th>Oligodendrocytes</th>
<th>Neurons</th>
</tr>
</thead>
<tbody>
<tr>
<td>14-3-3 isoforms/cell types</td>
<td>MS</td>
<td>OND</td>
<td>NNC</td>
<td>MS</td>
</tr>
<tr>
<td>β</td>
<td>maj (+)</td>
<td>maj (+)</td>
<td>no (-)</td>
<td>maj (+)</td>
</tr>
<tr>
<td>γ</td>
<td>min (+)</td>
<td>min (+)</td>
<td>no (-)</td>
<td>min (+)</td>
</tr>
<tr>
<td>ε</td>
<td>maj (+)</td>
<td>maj (+)</td>
<td>min (+)</td>
<td>no (-)</td>
</tr>
<tr>
<td>ζ</td>
<td>maj (+)</td>
<td>maj (+)</td>
<td>no (-)</td>
<td>maj (+)</td>
</tr>
<tr>
<td>η</td>
<td>min (+)</td>
<td>min (+)</td>
<td>no (-)</td>
<td>no (-)</td>
</tr>
<tr>
<td>θ</td>
<td>min (+)</td>
<td>min (+)</td>
<td>min (+)</td>
<td>no (-)</td>
</tr>
<tr>
<td>σ</td>
<td>minor (+)</td>
<td>minor (+)</td>
<td>minor (+)</td>
<td>no (-)</td>
</tr>
</tbody>
</table>

The present study includes four MS cases numbered #791, 744, 609, and 544 whose clinical profiles are given in a supplementary table on the AJP website, six non-MS neurological and psychiatric disease cases (OND) composed of #719 acute cerebral infarction, #786 acute cerebral infarction, #789 old cerebral infarction, #807 old cerebral infarction, #523 schizophrenia, and #826 schizophrenia, and six neurologically normal cases (NNC) composed of #66, #67, #89, #2623, and #2647, whose profiles are described in the Materials and Methods section.

The population size of the immunoreactive cells is expressed as maj, major (large) population; min, minor (small) population; and no, almost no population. The intensity of immunoreactivity is graded as (-) negative, (+) weak, and (++) intense.
dium containing 10\(^{-5}\) mol/L all trans retinoic acid (Sigma, St. Louis, MO), replated twice and then plated on a surface coated with Matrigel Basement Membrane Matrix (Becton Dickinson, Bedford, MA). They were incubated for another 2 weeks in feeding medium containing a cocktail of mitotic inhibitors, resulting in the enrichment of differentiated neurons (NTera2-N).36

**Western Blot Analysis**

To prepare total protein extract for Western blot analysis, the cells and tissues were homogenized in RIPA lysis buffer composed of 50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and a cock-
tail of protease inhibitors (Roche Diagnostics, Mannheim, Germany), followed by centrifugation at 12,000 rpm at room temperature for 20 minutes. The supernatant was collected for separation on a 12% SDS-polyacrylamide gel electrophoresis (PAGE) gel and the protein concentration was determined by a Bradford assay kit (Bio-Rad, Hercules, CA). After gel electrophoresis, the protein was transferred onto nitrocellulose membranes and immuno-labeled at room temperature overnight with a panel of anti-14-3-3 protein antibodies listed in Table 1. Then, the membranes were incubated at room temperature for 30 minutes with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG (Santa Cruz Biotechnology). The specific reaction was visualized with a Western blot detection system using a chemiluminescent substrate (Pierce, Rockford, IL). After the antibodies were stripped...
by incubating the membranes at 50°C for 30 minutes in stripping buffer composed of 62.5 mmol/L Tris-HCl (pH 6.7), 2% SDS, and 100 mmol/L 2-mercaptoethanol, the membranes were processed for relabeling with goat polyclonal antibody against human heat shock protein HSP60 (N-20; Santa Cruz Biotechnology) followed by incubation with horseradish peroxidase-conjugated anti-goat IgG (Santa Cruz Biotechnology). Densitometric analysis was performed using NIH image version 1.61 software to quantify the intensity of the immunoreactive bands.36

**Immunoprecipitation Experiments**

To prepare total protein extract for immunoprecipitation experiments, the cells were homogenized in M-PER lysis buffer (Pierce) with a cocktail of protease inhibitors fol-
followed by centrifugation at 12,000 rpm at room temperature for 20 minutes. After preclearance, the supernatant was incubated at 4°C for 1 hour with a panel of anti-14-3-3 protein antibodies or the same amount of normal rabbit IgG (Santa Cruz Biotechnology). It was then incubated with Protein G Sepharose (Amersham Bioscience, Piscataway, NJ). After several washes, the immunoprecipitates were processed for Western blot analysis using V9 antibody or mouse monoclonal antibody against GFAP (GA5; Nichrei).

**Two-Dimensional Gel Electrophoresis and Mass Spectrometry Analysis**

To prepare total protein extract for two-dimensional gel electrophoretic analysis, the cells were homogenized in...
rehydration buffer composed of 8 mol/L urea, 2% CHAPS, 0.5% carrier ampholytes (pH 4 to 6), 20 mmol/L dithiothreitol, 0.002% bromophenol blue, and a cocktail of protease inhibitors and phosphatase inhibitors (Sigma). Urea-soluble protein was separated by isoelectric focusing using the ZOOM IPGRunner system (Invitrogen) loaded with an immobilized pH 4.5 to 5.5 gradient strip. After the first dimension of isoelectric focusing, the protein was separated in the second dimension on a NuPAGE 4 to 12% polyacrylamide gel (Invitrogen). The gel was stained using Coomassie brilliant blue G-250 solution or the Silverquest silver staining kit (Invitrogen). It was transferred onto a polyvinylidene difluoride membrane for protein overlay and Western blot analysis. Spots of interest were excised from the gels, trypsinized, and processed for mass spectrometry (nanoESI-MS/MS) analysis followed by database searching using MASCOT software (Invitrogen Proteome, Yokohama, Japan).

Protein Overlay Analysis
To prepare the 14-3-3 protein-specific probe for protein overlay analysis, the open reading frame of the human 14-3-3 isoform gene (YWHAE, GenBank accession No. NM_006761) was amplified from the cDNA of NTERa2-N cells by the polymerase chain reaction using sense and anti-sense primers (5’atgatgatgacagactgtg3’ and 5’tcagttactgttcagctc3’). The polymerase chain reaction product was cloned into a prokaryotic expression vector pTrcHis-TOPO (Invitrogen). The expression of recombinant human 14-3-3 protein having an N-terminal Xpress tag for detection (rh14-3-3e) was induced in Escherichia coli by exposure to isopropyl β-thiogalactoside. The recombinant protein was further purified through a HiTrap chelating HP column (Amersham Bioscience) and by separation on a 12% SDS-PAGE gel. Recombinant human interferon-stimulated protein ISG15 fused to an N-terminal Xpress tag (rhISG15), a vimentin-binding protein in human cancer cells,37 was prepared for the control probe. The polyvinylidene difluoride membrane on which the gel was blotted was incubated at room temperature overnight with 1 μg/ml rh14-3-3e or rhISG15 probe, followed by immunolabeling with mouse monoclonal anti-Xpress antibody (Invitrogen) and horseradish peroxidase-conjugated anti-mouse IgG. After the probes and antibodies were stripped by incubating the membrane at 50°C for 30 minutes in stripping buffer, it was repeatedly relabeled with V9 antibody, GA5 antibody, or rabbit polyclonal antibodies specific for phosphorylated Ser-39, Ser-72, or Ser-83 epitopes of vimentin (Santa Cruz Biotechnology), followed by incubation with horseradish peroxidase-conjugated anti-mouse or rabbit IgG.

Results
Growth-Dependent Expression of 14-3-3 Isoforms in Cultured Human Astrocytes
To investigate the expression pattern of seven 14-3-3 isoforms in human neural cells, cultured human astrocytes, NTERa2-N neurons, and U-373MG astrocytoma cells, all of which were incubated in 10% FBS-containing culture medium, were processed for Western blot analysis using a panel of isomform-specific antibodies or the antibodies broadly reactive against all of the isoforms listed in Table 1. Cultured human astrocytes, neurons, and astrocytoma cells, along with
human brain homogenate, expressed substantial levels of 14-3-3 isoforms (Figure 1, a to h; lanes 1 to 4). In contrast, the 1 isoform was undetectable in human neural cells but was identified in HeLa cells (Figure 1i, lanes 1 to 5).

To study the effects of culture conditions on 14-3-3 protein levels, human astrocytes were incubated for 7 days in 10% FBS-containing culture medium or in the serum-free culture medium, which led to nearly complete growth arrest. The expression levels of 14-3-3 isoforms were elevated in human astrocytes incubated in the serum-containing growth-promoting condition. The expression was enhanced 3.3-, 1.6-, 2.2-, 10.0-, 18.7-, or 4.6-fold, respectively, compared with the levels under the serum-free growth-arrested condition when standardized against the levels of HSP60, a housekeeping gene product on the identical blots (Figure 2, a to c, e to g; top and bottom panels, lanes 1 and 2). The serum-induced up-regulation of 14-3-3 isoforms was also observed in a different culture of human astrocytes (Figure 2d, top and bottom panels, lanes 1 and 2; and additional data shown in Supplementary Figure 2 on The American Journal of Pathology website at http://www.amipathol.org). These results indicate that cultured human astrocytes constitutively express all iso-

Figure 8. Two-dimensional gel electrophoresis and immunoprecipitation analysis of 14-3-3 isoform-binding proteins in cultured human astrocytes. A: Two-dimensional gel analysis. Human astrocytes (AS-BW) were incubated in 10% FBS-containing culture medium. Twenty-one μg of total protein extract was separated on a two-dimensional PAGE gel, transblotted onto a polyvinylidene difluoride membrane, and processed for overlay analysis with recombinant human 14-3-3 protein possessing the Xpress tag (rh14-3-3) followed by labeling with anti-Xpress antibody. After the probe and antibody were stripped, the blot was repeatedly relabeled six times with the antibodies against GFAP, vimentin, and vimentin with specific phosphorylated serine epitopes, and with recombinant human interferon-stimulated protein ISG15 having the Xpress tag (rhISG15). a to g represent silver staining (a), rh14-3-3 labeling followed by staining with anti-Xpress antibody (b), vimentin (c), vimentin with phosphorylated Ser-39 (d), vimentin with phosphorylated Ser-72 (e), vimentin with phosphorylated Ser-83 (f), GFAP (g), and rhISG15 labeling followed by staining with anti-Xpress antibody (h). Two major spots labeled with rh14-3-3 and anti-vimentin antibody are named spot no. 1 and no. 2, while a spot labeled with rh14-3-3 and anti-GFAP antibody is designated spot no. 3. Spots no. 1 and no. 2 were excised from the gel and processed for mass spectrometry (MS) analysis. B: Immunoprecipitation analysis. Total protein extract of cultured human astrocytes was immunoprecipitated with 1 isoform-specific antibody (lanes 1 and 6), 2 isoform-specific antibody (lanes 2 and 7), 1 isoform-specific antibody (lanes 3 and 8), with the same amount of normal rabbit IgG (lanes 4 and 9), or untreated with any antibodies (lanes 5 and 10). 5 μg of total protein extract before processing for immunoprecipitation. Then, the immunoprecipitates were processed for Western blot analysis using anti-vimentin (top) or anti-GFAP antibody (bottom).
forms except for $\sigma$, whose levels were elevated in a cell growth-dependent manner.

Differential Expression of 14-3-3 Isoforms in Reactive Astrocytes in Demyelinating Lesions of MS

To investigate the differential expression of seven 14-3-3 isoforms in MS lesions, the brain, spinal cord, and optic nerve of four progressive MS patients (no. 791, no. 744, no. 609, and no. 544) and 12 non-MS control cases were processed for immunohistochemistry using a panel of isoform-specific antibodies. In chronic active and inactive demyelinating lesions of MS, the majority of GFAP$^+$ hypertrophic astrocytes intensely expressed $\beta$, $\epsilon$, $\zeta$, and $\eta$ isoforms, whereas a small population of reactive astrocytes displayed immunoreactivities against $\gamma$, $\theta$, and $\sigma$ isoforms (Table 2; Figure 3, a to e; Figure 4 a and b). Reactive astrocytes immunoreactive against the 14-3-3 protein exhibited the most dense accumulation at the lesion edge, although they were widely distributed in demyelinating lesions and in the normal appearing white matter. A glial scar was also intensely labeled with antibodies against $\beta$, $\epsilon$, $\zeta$, and $\eta$ isoforms ($\epsilon$ shown in Figure 3e and the others not shown). In MS and non-MS brains, a major population of cerebral cortical neurons constitutively expressed high levels of $\beta$, $\gamma$, $\zeta$, and $\eta$ isoforms, and to a lesser degree, $\theta$ isoform, whereas they hardly showed immunoreactivity for the $\sigma$ isoform, and a small population of cerebral cortical neurons in MS and non-MS brains occasionally expressed weak immunoreactivity for the $\epsilon$ isoform, although these findings varied among brains for different cases (Table 2; Figure 4, c to f; and Figure 6). Disrupted, distorted, and swollen axons found in the active demyelinating lesions of MS exhibited strong immunoreactivity against $\gamma$ and $\xi$ isoforms ($\gamma$ shown in Figure 5a and the other not shown).

A very small population of reactive astrocytes in demyelinating lesions of MS, which occasionally showed a binucleated morphology, intensely expressed the $\sigma$ isoform, whose expression was not detected in cultured human astrocytes (Figure 5c). A number of reactive astrocytes that appeared in the ischemic lesions of cerebral infarction expressed strong immunoreactivity against $\epsilon$, $\zeta$, and $\eta$ isoforms (Table 2; Figure 5b), and the $\sigma$ isoform was again strongly expressed in a very small number of reactive astrocytes (Figure 5d). The immunoreactivity against the $\eta$ isoform was often concentrated in the nuclear region of reactive astrocytes in MS lesions (not shown) and the ischemic lesions (Figure 6; a to f). Furthermore, some GFAP$^+$ astrocytes occasionally identified in the brains of schizophrenia and neurologically normal patients expressed $\epsilon$ and $\sigma$ isoforms at variable levels (Table 2; Figure 6, b and e). CD68$^+$ macrophages and microglia, with the greatest accumulation identified in the center and edge of active demyelinating lesions of MS and necrotic lesions of cerebral infarction, expressed $\beta$, $\zeta$, and $\eta$ isoforms, whereas they did not show substantial immunoreactivity against $\epsilon$, $\theta$, $\sigma$, or $\alpha$ isoforms (Table 2; Figure 6c). CD3$^+$ lymphocytes found in the perivascular cuffs of active MS lesions expressed variable immunoreactivities for $\beta$ and $\zeta$ isoforms (not shown). A substantial
population of oligodendrocytes, which survived in chronic active demyelinating lesions of MS and ischemic lesions of cerebral infarction, expressed intense immunoreactivity against \( p\)-isoform (Table 2; Figure 5, e and f; and Figure 6d). These results suggest that markedly up-regulated expression of the \( p\)-isoform is the most reliable marker for identifying reactive astrocytes in MS and non-MS brains. Co-expression of the \( p\)-isoform and GFAP was verified in reactive astrocytes in MS lesions (Figure 7; a to c) and cultured human astrocytes (Figure 7; d to f) by double immunolabeling.

**Binding of the 14-3-3 \( p\) Isoform to Vimentin and GFAP in Cultured Human Astrocytes**

To identify the binding partner of the 14-3-3 protein in human astrocytes, we performed a protein overlay anal-
the rhISG15 probe did not react with these spots, excluding isoforms in human astrocyte protein extract, when the lysate was incubated with the e, β, or ζ isoform-specific antibody (Figure 8B, top and bottom panels, lanes 1 to 3, 6 to 8). In contrast, only marginal bands were found in those with normal rabbit IgG (Figure 8B, top and bottom panels, lanes 4 and 9). Co-expression of the e isoform with vimentin and GFAP was verified in cultured human astrocytes (Figure 10; a to d) and in reactive astrocytes in demyelinating lesions of MS (Figure 10, e and f) by double immunolabeling.

Discussion

The present study showed that seven 14-3-3 isoforms are differentially expressed in reactive astrocytes in demyelinating lesions of MS. Human astrocytes in culture also expressed β, γ, ε, ζ, η, and θ isoforms whose levels were markedly elevated under the growth-promoting culture condition. In demyelinating lesions of MS, the majority of GFAP isoforms were intensely expressed in astrocytes in demyelinating lesions of MS and non-MS brains. Previous studies showed that the α isoform expression is confined to differentiated squamous epithelial cells. However, we found that some reactive astrocytes in MS and non-MS brains intensely expressed this isoform. Neurons constitutively expressed β, γ, ε, ζ, and η isoforms but they did not constantly express e or α isoforms. Macrophages and microglia in MS and non-MS lesions intensely expressed β, ε, ζ, and η isoforms, although the expression of these isoforms was found in reactive astrocytes appearing in non-MS brains. A substantial population of oligodendrocytes, surviving in active demyelinating lesions of MS and ischemic lesions of cerebral infarction, intensely expressed the θ isoform, consistent with the expression of this isoform in the white matter of the developing rat CNS. These observations are in agreement with our previous findings that the 14-3-3 protein is expressed not only in neurons but also in astrocytes, microglia, and oligodendrocytes in mouse brain cell cultures. The present observations suggest that up-regulated expression of the e isoform could be used as an immunohistochemical marker to identify reactive astrocytes at least in demyelinating lesions of MS and ischemic lesions of cerebral infarction. However, Lewy bodies in the Parkinson’s disease brain and a minor population of neurons in MS and non-MS brains express the e isoform, indicating that this isoform is not astrocyte-specific.

The biological role of e and α isoforms in human astrocyte function remains unknown. Increasing evidence indicates that isoform-specific function regulates the develop-
opment and differentiation of neural and nonneural cells. Particularly, the ε isoform plays a role in the regulation of various cellular signaling events. The 14-3-3ε gene is deleted in patients with Miller-Dieker syndrome, a human neuronal migration disorder presenting with the most severe form of lissencephaly (LIS) associated with facial abnormalities.39 ε Isoform-deficient mice are defective in neuronal migration during brain development.40 The multimolecular complex composed of the ε isoform, LIS1 and nade nuclear distribution gene E homolog-like 1 (NUDEL) regulates the activity of dynnein, a cytoplasmic motor protein, suggesting a role of ε in neuronal migration.40 Somatic homozygous deletion of the 14-3-3ε gene is frequently found in small cell lung cancers, supporting the idea that the ε isoform serves as a tumor suppressor gene.41 The 14-3-3ε isoform, by binding to the intracellular domain of the p75 neurotrophin receptor (NTR) in a NGF-dependent manner, promotes p75NTR-associated cell death executor (NADE)-mediated apoptosis.42 During apoptosis, the ε protein is cleaved by caspase-3 at a cleavage site located in the C-terminal hydrophobic tail, where the amino acid sequence is highly variable among different 14-3-3 isoforms.43 The ε isoform interacts with cdc25A and cdc25B phosphatases, key enzymes required for cell-cycle progression by activating cyclin-dependent kinases.44 Phosphorylation-dependent interaction of the ε isoform with heat shock transcription factor HSF1 restricts the location of HSF1 in the cytoplasm by keeping it in an inactive form.45 The ε isoform catalyzes the depolymerization and unfolding of mitochondrial precursor proteins in an ATP-dependent manner.46 Based on these observations, we propose that the ε isoform plays a regulatory role in proliferation, apoptosis, and stress responses in reactive astrocytes.

The α isoform constitutes a component of the G2/M cell-cycle checkpoint machinery.47 Exposure of the cells to DNA-damaging agents results in p53-dependent induction of the α isoform, which in turn arrests the cells in the G2/M phase by sequestering the cdc2-cyclin B1 complex in the cytoplasm.48 Therefore, the α isoform-deficient cells are unable to maintain cell-cycle arrest.49 Selective down-regulation of the α isoform because of the hypermethylation of CpG islands in its promoter region is responsible for the malignant transformation of breast cancer cells.49 whereas reduced expression of the α isoform allows human epidermal keratinocytes to escape replicative senescence.50 These observations raise the possibility that a population of reactive astrocytes with strong immunoreactivity against the α isoform might represent the cells responding to DNA damage at the site of demyelinating lesions in MS and ischemic lesions of cerebral infarction.

Reactive gliosis is characterized by hypertrophy and proliferation of astrocytes associated with enhanced expression of GFAP and vimentin, accompanied by increased production of growth factors, cytokines, neuropeptides, and extracellular matrix molecules.51,52 Astrocytes play a role in the repair of the blood-brain barrier, protection of neurons from glutamate excitotoxicity, and enhancement of neuronal survival by supplying neurotrophic factors.53 On the other hand, reactive astrocytes strongly inhibit neurite outgrowth by forming glial scars after CNS injury and inflammation.53,54 Through protein overlay and nanoESI-MS/MS analysis, we showed that vimentin is the major 14-3-3 protein-interacting protein expressed in cultured human astrocytes. Consistent with previous observations,55,56 we identified vimentin expression in reactive astrocytes in demyelinating lesions of MS. Astrocytes isolated from vimentin-deficient mice possess an abnormal filamentous network of GFAP.57,58 Furthermore, mice lacking vimentin and GFAP do not form proper glial scars after CNS injury, indicating that the type III IF family proteins play a pivotal role in cytoskeletal organization in astrocytes.59

In our study, the rh14-3-3ε probe strongly reacted with two distinct spots named no. 1 and no. 2 among five phosphovimentin-immunoreactive spots on the blot. Vimentin was immunoprecipitated with the ζ and β isoforms along with ε. These observations suggest that the interaction between vimentin and the 14-3-3 protein is not isoform-specific, and that the 14-3-3 protein-binding domain in vimentin might not include phosphorylated Ser-39, Ser-72, and Ser-83 epitopes. Protein overlay analysis identified GFAP as another binding partner of the 14-3-3ε isoform. Immunoprecipitation experiments verified the interaction between GFAP and the ε, ζ, or β isoform. However, a different spot strongly immunoreactive against GFAP but much weakly labeled with rh14-3-3ε was identified on the two-dimensional gel blot. This suggests that a substantial pool of cytoplasmic vimentin and GFAP proteins steadily interact with the 14-3-3 protein in human astrocytes.

Our observations raise the possibility that the 14-3-3 protein acts as an adaptor that connects vimentin and GFAP in cultured human astrocytes (Figure 11). Previous studies showed that vimentin and GFAP are co-expressed and co-polymerized in assembled filaments in astrocytes.58,60 supporting the view that the 14-3-3 protein not only bridges vimentin and GFAP one by one, but also bundles both of them in the same assembled filaments. All these proteins are expressed at much higher levels in reactive astrocytes, which require more efforts to coordinate the IF network compared with resting astrocytes (Figure 11). Several other binding partner candidates for vimentin in astrocytes include α-crystallin, which inhibits the in vitro assembly of GFAP,61 and the multiple endocrine neoplasia type 1 (MEN1) gene product named menin, which binds to vimentin and GFAP in glioma cells.62 The 14-3-3-ι isoform interacts with F-actin and Raf kinase in cultured mouse astrocytes, indicating its role in cytoskeletal rearrangement during cell growth and division.63,64 Importantly, a recent study using COS-7 cells overexpressing the 14-3-3 protein showed that phosphorylated vimentin binds to the 14-3-3 protein and limits the interaction of 14-3-3 with other 14-3-3-binding partners, thereby modulating Raf-dependent intracellular signaling.65 This study also found that vimentin does not have typical consensus 14-3-3-binding motifs.65 However, a close interaction of the 14-3-3 protein with phosphorylated vimentin affects the phosphorylation and dephosphorylation state of vimentin.66 Site-specific phosphorylation of vimentin and GFAP is mediated by
a range of protein kinases, including Rho kinase, cdc2 kinase, Ca^{2+}-calmodulin-dependent kinase II, protein kinases A and C, and Aurora-B kinase. They coordinately regulate dynamic equilibrium between the assembly and disassembly of IF proteins during mitosis. Furthermore, these kinases are identified as binding partners for the 14-3-3 protein. Therefore, our observations suggest that the 14-3-3 protein plays a role in the organization of IF proteins and IF-related kinases during conversion from resting astrocytes to reactive astrocytes. A role for 14-3-3 protein in IF dynamics is supported by our preliminary observations that suggest the effects of difopein, a specific inhibitor of 14-3-3 protein/ligand interaction, on the morphological characteristics of cultured human astrocytes.

Acknowledgments

We thank Dr. Mitsuru Kawai, Department of Neurology, National Center Hospital for Mental, Nervous, and Muscular Disorders, NCNP, Tokyo, Japan, for providing information about MS patients; Dr. Toshikazu Murakami, Department of Pathology, Kohnodai Hospital, NCNP, Chiba, Japan, for providing the brains of neurologically normal controls; Drs. Kazuhiko Watabe and S.U. Kim, University of British Columbia, Vancouver, BC, Canada, for providing cultured fetal human astrocytes; and Dr. Masashi Fukuda, Invitrogen Proteome, Yokohama, Japan, for his help in nanoESI-MS/MS analysis.

References

45. Satoh et al. AJP August 2004, Vol. 165, No. 2